Insulin and glucose profiles during continuous subcutaneous insulin infusion compared with injection of a long-acting insulin in Type 2 diabetes

Diabetic Medicine

Volumn 25, Issue 5, 2008, Pages 585-591

  Parkner, T ^a   Laursen, T ^b   Vestergaard, E T ^a   Hartvig, H ^c   Smedegaard, J S ^c   Lauritzen, T ^b   Christiansen, J S ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Continuous subcutaneous insulin infusion; Insulin analogues; Insulin pharmacokinetics; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE PLUS METFORMIN; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN GLARGINE; METFORMIN; REPAGLINIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

AREA UNDER CURVE; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 42549103096     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02418.x     Document Type: Article

References (30)

1. Stratton IM, Adler AI, Neil HA, Matthews SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000 321 : 405 412.
2. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000 23 : B21 B29.
3. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in Type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998 15 : 290 296.
4. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002 25 : 330 336.
5. European Diabetes Policy Group 1999. A desktop guide to Type 2 diabetes mellitus. Diabet Med 1999 16 : 716 730.
6. Davis T, Edelman SV. Insulin therapy in type 2 diabetes. Med Clin North Am 2004 88 : 865 895.
7. Starke AA, Heinemann L, Hohmann A, Berger M. The action profiles of human NPH insulin preparations. Diabet Med 1989 6 : 239 244.
8. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004 66 : 193 201.
9. 125I-labelled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000 23 : 813 819.
10. Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004 53 : 1614 1620.
11. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007 9 : 290 299.
12. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007 9 : 648 659.
13. Lauritzen T. Pharmacokinetic and clinical aspects of intensified subcutaneous insulin therapy. Dan Med Bull 1985 32 : 104 118.
14. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006 29 : 1269 1274.
15. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003 26 : 3080 3086.
16. Duckworth W, Davis SN. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. J Diabetes Complications 2007 21 : 196 204.
17. Parkner T, Laursen T, Chen JW, Moller MK, Thomsen HF, Jorgensen C et al. Overnight versus 24 hours of continuous subcutaneous insulin infusion as supplement to oral anti-diabetic drugs in type 2 diabetes. J Diabetes Sci Technol 2007 1 : 704 710.
18. Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993 39 : 578 582.
19. Andersen L, Jorgensen PN, Jensen LB, Walsh D. A new insulin immunoassay specific for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence, and pharmacokinetic studies. Clin Biochem 2000 33 : 627 633.
20. Gimeno-Orna JA, Castro-Alonso FJ, Boned-Juliani B, Lou-Arnal LM. Fasting plasma glucose variability as a risk factor of retinopathy in Type 2 diabetic patients. J Diabetes Complications 2003 17 : 78 81.
21. Muggeo M, Zoppini G, Bonora E, Bonadonna RC, Moghetti P et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000 23 : 45 50.
22. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000 23 : 644 649.
23. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000 49 : 2142 2148.
24. Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 2005 48 : 1988 1995.
25. DeVries JH. To: Scholtz HE, Pretorius SG, Wessels DH, Becker RHA. Diabetologia 2005 48 : 1988 1995. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 2006 49 : 1125 1126.
26. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen T, Schmid C et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000 49 : 999 1005.
27. Reynolds NA, Wagstaff AJ. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus. Drugs 2004 64 : 1957 1974.
28. Dunn CJ, Plosker GL, Keating GM, McKeage K, Scott LJ. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs 2003 63 : 1743 1778.
29. Lauritzen T, Pramming S, Gale EA, Deckert T, Binder C. Absorption of isophane (NPH) insulin and its clinical implications. Br Med J (Clin Res Ed) 1982 285 : 159 162.
30. Carroll MF, Schade DS. The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract 2005 11 : 55 64.